Response to third-line endocrine treatment for advanced breast cancer
Authors:
- Julie AhernJAJulie Ahern
- Ian E. SmithISIan E. Smith
- 1 January 1993
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 29 (4) , 572-574
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Norethisterone acetate as secondary endocrine treatment in advanced breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Megestrol acetate versus aminoglutethimide for metastatic breast cancerBreast Cancer Research and Treatment, 1989
- LHRH analogues in the treatment of cancerCancer Treatment Reviews, 1989
- Aromatase inhibitors in the treatment of advanced breast cancerCancer Treatment Reviews, 1989
- Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancerEuropean Journal of Cancer and Clinical Oncology, 1989
- Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast CarcinomauJNCI: Journal of the National Cancer Institute, 1988
- Additive hormonal therapy in women with advanced breast cancerCancer, 1984
- Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial.BMJ, 1981
- Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A reviewBreast Cancer Research and Treatment, 1981
- Randomized Clinical Trial of Diethylstilbestrol versus Tamoxifen in Postmenopausal Women with Advanced Breast CancerNew England Journal of Medicine, 1981